China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with a local company in Pakistan. The collaboration aims to work together on the regulatory filing, distribution, and licensing of Kangtai’s 13-valent and 23-valent pneumonia vaccines in the Pakistani market.
Pakistan’s Vaccination Plan and Market Opportunity
Pakistan, with a population of 230 million, has included six vaccines in its national vaccination plan. This presents a significant opportunity for Kangtai to expand its market reach and contribute to the country’s public health efforts. The partnership is expected to facilitate the introduction of Kangtai’s advanced pneumonia vaccines, enhancing the vaccination options available in Pakistan.
Kangtai’s Global Expansion Strategy
Kangtai has previously entered into similar agreements focused on its pneumococcal infection vaccines with local companies in Indonesia, the Philippines, Egypt, and other countries. These partnerships are part of Kangtai’s broader strategy to expand its global footprint and make its vaccines more accessible to populations in need. The new partnership in Pakistan further solidifies Kangtai’s position as a leading provider of pneumonia vaccines in emerging markets.-Fineline Info & Tech
